DOP2011000335A - Combinacion antitumoral que comprende ave8062 y sorafenib - Google Patents

Combinacion antitumoral que comprende ave8062 y sorafenib

Info

Publication number
DOP2011000335A
DOP2011000335A DO2011000335A DO2011000335A DOP2011000335A DO P2011000335 A DOP2011000335 A DO P2011000335A DO 2011000335 A DO2011000335 A DO 2011000335A DO 2011000335 A DO2011000335 A DO 2011000335A DO P2011000335 A DOP2011000335 A DO P2011000335A
Authority
DO
Dominican Republic
Prior art keywords
ave8062
sorafenib
combination including
antitumoral combination
antitumoral
Prior art date
Application number
DO2011000335A
Other languages
English (en)
Inventor
Brigitte Demers
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2011000335A publication Critical patent/DOP2011000335A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La ¡nvención se refiere a una combinación farmacéutica antitumoral que comprende AVE8062 de fórmula (l) y sorafenib de fórmula (11), pudiendo estar estos dos agentes antitumorales en forma e base o en forma de una sal de un ácido farmacéuticamente aceptable.
DO2011000335A 2009-05-07 2011-11-02 Combinacion antitumoral que comprende ave8062 y sorafenib DOP2011000335A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
DOP2011000335A true DOP2011000335A (es) 2011-12-15

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000335A DOP2011000335A (es) 2009-05-07 2011-11-02 Combinacion antitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
BR112012031917A2 (pt) * 2010-06-18 2017-11-28 Sanofi Sa combinação antitumoral compreendendo ombrabulina, um derivado de taxano e um derivado de platina
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999051246A1 (en) * 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Antitumor agents
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
PT1407784E (pt) * 2001-06-25 2011-03-03 Ajinomoto Kk Agentes antitumorais
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
ECSP11011440A (es) 2011-12-30
JP2012526090A (ja) 2012-10-25
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
PE20120323A1 (es) 2012-04-17
CA2761146A1 (fr) 2010-11-11
BRPI1014197A2 (pt) 2016-04-26
FR2945210B1 (fr) 2011-07-01
EP2427185A1 (fr) 2012-03-14
IL216133A0 (en) 2012-01-31
TW201043225A (en) 2010-12-16
KR20120023754A (ko) 2012-03-13
AU2010244254A1 (en) 2011-11-24
CL2011002782A1 (es) 2012-03-30
CO6390102A2 (es) 2012-02-29
TN2011000551A1 (fr) 2013-05-24
ZA201108110B (en) 2013-01-30
AR076848A1 (es) 2011-07-13
CN102438608A (zh) 2012-05-02
CR20110573A (es) 2011-12-08
FR2945210A1 (fr) 2010-11-12
MX2011011767A (es) 2012-02-28
EA201171366A1 (ru) 2012-05-30
MA33346B1 (fr) 2012-06-01
US20120108641A1 (en) 2012-05-03
UY32618A (es) 2010-12-31
NI201100191A (es) 2012-01-16

Similar Documents

Publication Publication Date Title
DOP2011000335A (es) Combinacion antitumoral que comprende ave8062 y sorafenib
AR077629A1 (es) Mimetico de smac
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
IN2014DN10670A (es)
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
MX395271B (es) Composicion farmaceutica.
CO7180201A2 (es) Inhibidores de neprilisina
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
UY32408A (es) Macrolido anti-inflamatorio
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion